Pipeline Update from BioDelivery Sciences - Analyst Blog
15 Janvier 2014 - 12:50AM
Zacks
Pipeline updates are highly awaited events in the pharma/biotech
sector as they play an important role in deciding whether or not to
invest in a particular company. These updates provide information
on experimental drugs and at times give an insight into the
commercial potential of the candidate once it is successfully
developed and commercialized.
With the commencement of 2014, several companies have been
providing an update on their pipelines as well as goals for the
year. BioDelivery Sciences International, Inc.
(BDSI) has important catalysts coming up this year with the
database for a phase III study on its lead candidate, BEMA
buprenorphine, expected to be locked soon.
BEMA buprenorphine is being developed for the treatment of
moderate to severe chronic pain in opioid naive subjects and
topline data from the phase III study should be out later this
month/early next month.
BioDelivery Sciences has a licensing and development agreement
with Endo Health Solutions, Inc. (ENDP) for BEMA
buprenorphine. According to the agreement, BioDelivery Sciences
will receive a milestone payment of $10 million from Endo once the
database for the phase III study is locked.
Meanwhile, the database for a second phase III trial on BEMA
buprenorphine (for opioid experienced patients) is scheduled to be
locked by mid-2014. The company expects to file a New Drug
Application (NDA) for the candidate in late 2014.
BioDelivery Sciences continues to work on its commercialization
plans for Bunavail, which is currently under FDA review for
maintenance treatment of opioid dependence. A response should be
out by Jun 7, 2014. The re-launch of Onsolis (management of
breakthrough pain in opioid tolerant patients with cancer) is
slated for the second half of the year.
BioDelivery Sciences also said that it intends to commence a
phase III study on clonidine topical gel in the first quarter for
the treatment of painful diabetic neuropathy.
We expect investor focus to remain on the phase III BEMA
buprenorphine data that should be out in the coming weeks.
BioDelivery Sciences carries a Zacks Rank#3 (Hold). Some better
ranked stocks in the same sector include Actelion
Ltd. (ALIOF) and Acceleron Pharma, Inc.
(XLRN). While Actelion (ALIOF) is a Zacks Rank #1 (Strong Buy)
stock, Acceleron Pharma (XLRN) is a Zacks Rank #2 (Buy) stock.
ACTELION LTD (ALIOF): Get Free Report
BIODELIVERY SCI (BDSI): Free Stock Analysis Report
ENDO PHARMACEUT (ENDP): Free Stock Analysis Report
ACCELERON PHARM (XLRN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(USOTC:ALIOF)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(USOTC:ALIOF)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024